Metabolic and cardiovascular risks of androgen-deprivation therapy for prostate cancer

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin.59(4), 225–249 (2009).
   PubMed Web of Science ®Google Scholar
• Huggins C, Hodges CV. Studies on prostate cancer. I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res.1, 293–297 (1941).
   Google Scholar
• Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg.43, 209–233 (1941).
   Google Scholar
• Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med.337(5), 295–300 (1997).
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA292(7), 821–827 (2004).
   PubMed Web of Science ®Google Scholar
• Roach M 3rd, Bae K, Speight J et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol.26(4), 585–591 (2008).
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J. Clin. Oncol.22(11), 2141–2149 (2004).
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J. Natl Cancer Inst.95, 981–989 (2003).
   PubMedGoogle Scholar
• Lu-Yao GL, Albertsen PC, Moore DF et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA300(2), 173–181 (2008).
   PubMed Web of Science ®Google Scholar
• DiBlasio CJ, Malcolm JB, Hammett J et al. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience. BJU Int.104(9), 1208–1214 (2009).
   Google Scholar
• Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. Eur. Urol.56(4), 609–616 (2009).
   Google Scholar
• Namiki M, Mizokami A, Akaza H. Should patients with localized prostate cancer receive primary androgen deprivation therapy? Nat. Clin. Pract. Urol.5, 648–649 (2008).
   Google Scholar
• Akaza H, Homma Y, Usami M et al. Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int.98, 573–579 (2006).
   Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA294(2), 238–244 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer115(11), 2388–2399 (2009).
   PubMed Web of Science ®Google Scholar
• Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J. Gen. Intern. Med.24(Suppl. 2), S389–S394 (2009).
   Google Scholar
• Schwandt A, Garcia JA. Complications of androgen deprivation therapy in prostate cancer. Curr. Opin. Urol.19(3), 322–326 (2009).
   PubMed Web of Science ®Google Scholar
• Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol.163(1), 181–186 (2000).
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med.352(2), 154–164 (2005).
   PubMed Web of Science ®Google Scholar
• Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br. J. Urol.79(6), 933–941 (1997).
   PubMedGoogle Scholar
• Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.Cancer104(8), 1633–1637 (2005).
   PubMed Web of Science ®Google Scholar
• Smith MR, O’Malley AJ, Keating NL. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? BJU Int.101(11), 1335–1336 (2008).
   Google Scholar
• Smith MR, Finkelstein JS, McGovern FJ et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J. Clin. Endocrinol. Metab.87(2), 599–603 (2002).
   PubMed Web of Science ®Google Scholar
• Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J. Clin. Endocrinol. Metab.90(2), 657–660 (2005).
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J. Clin. Endocrinol. Metab.91(4), 1305–1308 (2006).
   PubMed Web of Science ®Google Scholar
• Mårin P, Holmäng S, Jönsson L et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.Int. J. Obes. Relat. Metab. Disord.16(12), 991–997 (1992).
   PubMed Web of Science ®Google Scholar
• Smith JC, Bennett S, Evans LM et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J. Clin. Endocrinol. Metab.86(9), 4261–4267 (2001).
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee H, McGovern FJ et al. Metabolic changes during gonadotropin releasing hormone (GnRH) agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer112(10), 2188–2194 (2008).
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol.24(27), 4448–4456 (2006).
   PubMed Web of Science ®Google Scholar
• Lage MJ, Barber BL, Markus RA. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology70(6), 1104–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Alibhai SM, Duong-Hua M, Sutradhar R et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J. Clin. Oncol.27(21), 3452–3458 (2009).
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J. Natl Cancer Inst.102(1), 39–46 (2009).
   Google Scholar
• Derweesh IH, DiBlasio CJ, Kincade MC et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int.100(5), 1060–1065 (2007).
   PubMed Web of Science ®Google Scholar
• Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma.Cancer83(6), 1180–1188 (1998).
   PubMed Web of Science ®Google Scholar
• Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.Cancer110(7), 1493–1500 (2007).
   PubMed Web of Science ®Google Scholar
• Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst.99(20), 1516–1524 (2007).
   PubMed Web of Science ®Google Scholar
• Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA302(8), 866–873 (2009).
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol.25(17), 2420–2425 (2007).
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA299(3), 289–295 (2008).
   PubMed Web of Science ®Google Scholar
• Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J. Clin. Oncol.24(12), 1868–1876 (2006).
   PubMedGoogle Scholar
• Efstathiou JA, Bae K, Shipley WU et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur. Urol.54(4), 816–823 (2008).
   Google Scholar
• Efstathiou JA, Bae K, Shipley WU et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J. Clin. Oncol.27(1), 92–99 (2009).
   PubMed Web of Science ®Google Scholar
• Bolla M, de Reijke TM, Van Tienhoven G et al.; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med.360(24), 2516–2527 (2009).
   PubMed Web of Science ®Google Scholar
• Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol.181(5), 1998–2006 (2009).
   PubMed Web of Science ®Google Scholar
• Bagrodia A, DiBlasio CJ, Wake RW, Derweesh IH. Adverse effects of androgen deprivation therapy in prostate cancer: current management issues.Indian J. Urol.25(2), 169–176 (2009).
   PubMedGoogle Scholar
• Gomella LG. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int.99(Suppl. 1), 25–29 (2007).
   PubMedGoogle Scholar